omniture

China Cord Blood Corporation Reports Second Quarter and First Half Fiscal 2011 Financial Results

2010-11-24 19:13 1283

29.4% Increase in 2Q11 Revenue

24.6% Increase in 2Q11 Net Income Attributable to Shareholders

Conference Call to be Held at 8 am ET November 24, 2010

HONG KONG, Nov. 24, 2010 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the second quarter and first half of fiscal 2011 ended September 30, 2010.

Second Quarter of Fiscal 2011 Highlights

  • Net revenue increased 29.4% to RMB82.7 million ($12.4 million).
  • New subscriber sign-ups grew 22.5% to 13,932.
  • Gross profit increased 37.3% to RMB63.5 million ($9.5 million).
  • Gross margin expanded more than 4 percentage points to 76.8%.
  • Operating income increased 20.9% to RMB29.2 million ($4.4 million).
  • Net income attributable to shareholders increased 24.6% to RMB22.0 million ($3.3 million).

First Half of Fiscal 2011 Highlights

  • Net revenue increased 26.7% to RMB154.4 million ($23.1 million).
  • New subscriber sign-ups grew 20.0% to 26,112.
  • Gross profit increased 34.2% to RMB118.0 million ($17.6 million).
  • Gross margin expanded more than 4 percentage points to 76.4%.
  • Operating income increased 11.3% to RMB52.5 million ($7.9 million).
  • Net income attributable to shareholders reached RMB39.6 million ($5.9 million).

Ms. Ting Zheng, Chairperson and Chief Executive Officer of China Cord Blood Corporation, commented, "We are very pleased with our solid performance in the second quarter of fiscal 2011, which reflects our ongoing achievements to continuously penetrate our Beijing and Guangdong market.  It was also the first time our quarterly new subscriber numbers exceeded the 13,000 mark and set new records in terms of revenue and profit.  Alongside our encouraging sales performance, margins also improved on the back of economies of scale and the recurring storage fee revenue of our business.  We are even more excited by the fact that general public in Beijing and Guangdong is becoming increasingly receptive towards umbilical cord blood stem cells banking services.  In view of China's one-child policy, one-license per region regime and over 1.2 million babies born in Beijing and Guangdong each year, we are confident in setting new records for the future quarters to come." 

 

Summary – The Quarter and the First Half ended September 30, 2009 and 2010
Three Months Ended Six Months Ended
September 30, September 30,
2009 2010 2009 2010
RMB('000) RMB('000) USD('000) RMB('000) RMB('000) USD('000)
Revenue 63,897 82,682 12,358 121,826 154,378 23,074
Gross Profit 46,265 63,528 9,495 87,938 117,972 17,633
Operating Income 24,144 29,194 4,364 47,199 52,549 7,856
Net Income Attributable to Shareholders 17,639 21,982 3,286 13,047 39,569 5,915
EPS Attributable to Ordinary Shares
– Basic (RMB/USD) 0.29 0.33 0.05 0.12 0.59 0.09
Revenue Breakdown (%)
Processing Fee 82.6% 79.4% 83.3% 79.3%
Storage Fee 17.4% 20.6% 16.7% 20.7%
New Subscribers (persons) 11,371 13,932 21,752 26,112
Accumulated Total Number of Subscribers
(persons) 105,812 155,424 105,812 155,424

Second Quarter Fiscal 2011 Financial Results

REVENUE. Second quarter revenue increased 29.4% to RMB82.7 million ($12.4 million), up from RMB63.9 million in the same period last year.  Revenue from processing fee increased by 24.4% to RMB65.6 million ($9.8 million) as the number of new subscribers signed up during the second quarter increased by 22.5% to 13,932.  Revenue from storage fees increased 53.2% year-over-year to RMB17.1 million ($2.6 million) and the accumulated subscriber base as of September 30, 2010 reached 155,424, up 46.9% year-over-year. Revenue from storage fee accounted for 20.6% of the total second quarter revenue, compared to 17.4% in the same period last year.

GROSS PROFIT. Second quarter gross profit increased to RMB63.5 million ($9.5 million), up 37.3% from RMB46.3 million in the same period last year. Aside from the strong revenue growth we also benefited economies of scale and an increase in revenue from storage fees which resulted more than four percentage points margin expansion to 76.8%.

OPERATING INCOME. Operating income reached RMB29.2 million ($4.4 million), up 20.9% from RMB24.1 million. The increase in operating income was largely attributable to robust revenue growth and favorable margin expansion. Operating income as a percentage of revenues stood at 35.3%, representing a steady sequential improvement.

Research and Development expense. Second quarter research and development expense amounted to RMB1.8 million ($0.3 million) due to the Company's effort aimed to improve cost structure and operational efficiency.

Sales and Marketing expense. Consistent with the ongoing effort to broaden market coverage and deepen market penetration, second quarter sales and marketing expense increased 23.4% to RMB11.7 million ($1.7 million). It also reflected the Company's commitment to support rising demand and sales activities. With management's effective cost control effort and robust revenue growth, sales and marketing expense as a percentage of revenue remained stable at 14.1%. 

General Administrative expense. Second quarter general administration expenses amounted to RMB20.9 million ($3.1 million). General administrative expense as a percentage of revenue retreated to 25.2%. Management effort to monitor and control overall administrative expense has yielded preliminary success and overall administrative expense remains stable on a quarter on quarter basis. 

NET INCOME ATTRIBUTABLE TO SHAREHOLDERS. Second quarter net income attributable to shareholders reached RMB22.0 million ($3.3 million).  Net margin for the second quarter of fiscal 2011 was 26.6% which also represented a steady improvement sequentially. Basic earnings per share for second quarter of fiscal 2011 were RMB0.33 ($0.05).

NET CASH. As of September 30, 2010, the Company had cash and cash equivalents of RMB338.6 million ($50.6 million), compared to RMB280.8 million as of March 31, 2010. As of September 30, 2010, total borrowing was RMB45 million ($6.7 million).

Ms. Zheng concluded, "Our solid track record is a strong testimony with respect to our ability to commercialize, penetrate, and grow our business.  As we continue to penetrate the Beijing and Guangdong market, we also invested in the Shandong cord blood bank and have executed geographical expansion initiative by securing our position for Zhejiang province.  Being the only operator with multiple licenses reflected our competitive advantage to seize merger and acquisition opportunities and our management team's ability to commercialize the cord blood banking services in new regions.  As strong growth is expected from existing Beijing municipality and Guangdong province and in the future Zhejiang province, we will also monitor other emerging opportunities both inside and outside of China."

First Half Fiscal 2011 Financial Results

For first half of fiscal 2011, total revenue increased 26.7% to RMB154.4 million ($23.1 million), from RMB121.8 million last year. The increase was largely attributable to the 20.0% increase in new subscriber numbers to 26,112 new subscribers and the expansion in the accumulated subscriber base to 155,424 subscribers. During the first half of the year, processing fees and storage fees grew 20.5 % and 57.6%, respectively. Gross profit in the first half of fiscal 2011 increased 34.2% to RMB118.0 million ($17.6 million) from RMB 87.9 million in the prior year period.  In the first half of fiscal 2011, operating income increased to RMB52.5 million ($7.9 million). First half fiscal 2011 net income attributable to shareholders was RMB39.6 million ($5.9 million). Basic earnings per share attributable to ordinary shares were RMB0.59 ($0.09).

Financial Outlook

The Company reaffirms its previously issued guidance and expects the number of new subscribers for the fiscal year 2011 to exceed 58,000, which would translate into at least a 30% increase in net revenue.  The management team also expects to have an accumulated total number of at least 187,000 subscribers at the end of fiscal 2011.

Conference Call

The Company will hold a teleconference at 8:00 a.m. ET on Wednesday, November 24, 2010 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the following link: http://investor.chinacordbloodcorp.com/playerlink.zhtml?c=206671&s=wm&e=3489976.  A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 22793903.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit our website at http://www.chinacordbloodcorp.com. 

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ended September 30, 2010 were made at the noon buying rate of RMB6.6905 to $1.00 on September 30, 2010 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

 

For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, LLC
In New York: Ashley M. Ammon or Christine Duan: 1-646-277-1227

In Beijing: Wen Lei Zheng: +86-10-6583-7510


CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
As of March 31 and September 30, 2010

March 31, September 30,
2010 2010
RMB RMB US$
(in thousands except share data)
ASSETS
Current assets
Cash and cash equivalents 280,835 338,641 50,615
Accounts receivable, less allowance for doubtful accounts
(March 31, 2010: RMB8,016; September 30, 2010: RMB10,073) 61,349 56,609 8,461
Inventories 5,070 6,491 970
Prepaid expenses and other receivables 13,137 10,848 1,621
Deferred tax assets 3,443 4,441 664
Total current assets 363,834 417,030 62,331
Property, plant and equipment, net 250,491 246,756 36,882
Non-current prepayments 151,138 7,260 1,085
Non-current accounts receivable, less allowance for doubtful accounts
(March 31, 2010: RMB9,181; September 30, 2010: RMB15,976) 176,874 211,360 31,591
Inventories 29,637 31,527 4,712
Intangible asset, net 26,297 25,812 3,858
Available-for-sale equity securities 48,475 51,462 7,692
Other investment - 137,729 20,586
Deferred tax assets 288 506 76
Total assets 1,047,034 1,129,442 168,813
LIABILITIES
Current liabilities
Bank loan 45,000 45,000 6,726
Accounts payable 5,410 6,657 994
Accrued expenses and other payables 22,475 20,643 3,086
Deferred revenue 36,074 53,370 7,977
Amounts due to related parties 2,977 720 107
Income tax payable 4,098 6,920 1,034
Total current liabilities 116,034 133,310 19,924
Deferred revenue 93,155 118,601 17,727
Other non-current liabilities 15,978 20,859 3,118
Deferred tax liabilities 2,259 836 125
Total liabilities 227,426 273,606 40,894

CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
As of March 31 and September 30, 2010 – (continued)

March 31, September 30,
2010 2010
RMB RMB US$
(in thousands except share data)
EQUITY
Shareholders' equity
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 66,743,693 shares and 66,997,200 shares issued and outstanding as of March 31 and September 30, 2010, respectively 46 46 7
Additional paid-in capital 719,329 727,911 108,797
Accumulated other comprehensive income/(loss) 2,221 (12,853) (1,921)
Retained earnings 87,290 126,859 18,962
Total shareholders' equity 808,886 841,963 125,845
Noncontrolling interests 10,722 13,873 2,074
Total equity 819,608 855,836 127,919
Total liabilities and equity 1,047,034 1,129,442 168,813

CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months and Six Months Ended September 30, 2009 and 2010

Three months ended September 30, Six months ended September 30,
2009 2010 2009 2010
RMB RMB US$ RMB RMB US$
(in thousands except per share data)
Revenues 63,897 82,682 12,358 121,826 154,378 23,074
Direct costs (17,632) (19,154) (2,863) (33,888) (36,406) (5,441)
Gross profit 46,265 63,528 9,495 87,938 117,972 17,633
Operating expenses
Research and development - (1,794) (268) - (3,337) (499)
Sales and marketing (9,470) (11,684) (1,746) (16,512) (21,774) (3,254)
General and administrative (12,651) (20,856) (3,117) (24,227) (40,312) (6,024)
Total operating expenses (22,121) (34,334) (5,131) (40,739) (65,423) (9,777)
Operating income 24,144 29,194 4,364 47,199 52,549 7,856
Other income/(expense), net
Interest income 1,723 1,587 237 2,755 4,038 604
Interest expense (657) (672) (100) (1,117) (1,278) (191)
Exchange gain 451 827 124 563 590 88
Impairment loss on available- for-sale equity securities - - - (21,566) - -
Others 83 774 116 377 890 132
Total other income/(expense), net 1,600 2,516 377 (18,988) 4,240 633
Income before income tax 25,744 31,710 4,741 28,211 56,789 8,489
Income tax expense (6,367) (8,112) (1,213) (12,141) (14,222) (2,126)
Net income 19,377 23,598 3,528 16,070 42,567 6,363
Income attributable to noncontrolling interests (1,391) (1,616) (242) (2,676) (2,998) (448)
Income attributable to redeemable noncontrolling interests (347) - - (347) - -
Net income attributable to
shareholders 17,639 21,982 3,286 13,047 39,569 5,915
Net income per share:
Attributable to ordinary shares
-Basic 0.29 0.33 0.05 0.12 0.59 0.09
-Diluted 0.27 0.33 0.05 0.11 0.58 0.09
Attributable to redeemable ordinary shares
-Basic N/A N/A N/A 0.92 N/A N/A
-Diluted N/A N/A N/A 0.92 N/A N/A
Source: China Cord Blood Corporation
Related Stocks:
NYSE:CO
collection